Herbert Loong, Clinical Associate Professor at The Chinese University of Hong Kong, shared on LinkedIn:
“Thanks MSD Hong Kong for organising the Hong Kong iteration of Current Trends In Oncology (CTIO26). Always a pleasure meeting colleagues and friends from across the city on a Saturday afternoon.
Had the opportunity to speak on Innovative Advances in SCLC, and also learned a lot from colleagues who treat other therapeutic areas.”
_____
Herbert Loong was recognized among OncoDaily’s Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024, highlighting his contributions to the field of oncology.
Nominations for Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024, recognizing leaders, researchers, clinicians, innovators, advocates, and other individuals making a meaningful impact on oncology and cancer care.
Don’t miss the opportunity to nominate yourself, a colleague, or someone whose contributions deserve to be recognized.
Submit your nomination by September 15.
You may also find this interesting:
XPO1 Inhibition May Reprogram Immune Resistance in SCLC: The TRIM21–IRF3–TNFSF15–TREM2 Axis
